3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
43
Carcinoma, Hepatocellular
19
Rectal Neoplasms
10
Colonic Neoplasms
10
Neoplasm Metastasis
9
Gastrointestinal Stromal Tumors
8
Sarcoma
5
Ovarian Neoplasms
5
Cholangiocarcinoma
5
Melanoma
4
Pancreatic Neoplasms
3
Osteosarcoma
3
Liver Neoplasms
3
Glioblastoma
3
Stomach Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Gallbladder Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Colorectal Cancer Metastatic
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Thyroid Neoplasms
1
Thymoma
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Interventions
Fluorouracil
13
Cisplatin
7
Radiotherapy
6
Specimen Handling
5
Mitomycin
5
Capecitabine
5
pembrolizumab
4
dehydroftorafur
4
Radiation
4
Drug Therapy
4
Cetuximab
4
Radiotherapy, Intensity-Modulated
3
Paclitaxel
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Carboplatin
3
Biopsy
3
tislelizumab
2
durvalumab
2
aldesleukin
2
VGX-3100
2
Platinum
2
Mitozytrex
2
Immune Checkpoint Inhibitors
2
Fluorodeoxyglucose F18
2
1,2-diaminocyclohexaneplatinum II citrate
2
toripalimab
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
spartalizumab
1
rocakinogene sifuplasmid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Anus Neoplasms
×
regorafenib
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn